
|Articles|November 13, 2012
Celgene Stock Soars on Promising Pancreatic Cancer Drug Data
Advertisement
Celgene, which unexpectedly reported the results late on Friday, did not give details of the extent of the improvement, saying it would do so at a medical meeting in January.
Abraxane is already approved to treat breast and lung cancer and the company will apply for approval from regulators to market the drug to treat pancreatic cancer as well.
Read the full story:
Source: Reuters
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Real-World Data Show Most CRS, ICANS Cases Happen Within 15 Days of Liso-Cel Infusion
2
Real-World Usage of Nintedanib for PPF Differs From Trial Settings
3
From Trial Diversity to Telehealth: Advancing Equity and Access in Rural and Underserved Cancer Care
4
Long-Term Adalimumab Improves Work, Life Quality in Psoriasis
5













































